The MAGNETOM Viato.Mobile may facilitate improved access to MRI capabilities for patients with serious health conditions who lack geographic proximity to centers with advanced imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the MAGNETOM Viato.Mobile, a 1.5 Tesla magnetic resonance imaging (MRI) system that is reportedly designed for easy transportation to off-site locations.
The 70 centimeter-bore scanner offers a variety of features including BioMatrix Technology and Deep Resolve image reconstruction, according to Siemens Healthineers, the manufacturer of MAGNETOM Viato.Mobile.
The company said the artificial intelligence (AI)-powered Deep Resolve technology accelerates scan times for brain scans by up to 70 percent, enhances image resolution and improves signal-to-noise ratio. Siemens Healthineers added that BioMatrix Technology prevents variation in imaging results by enabling clinicians to personalize MRI exams and compensate for different patient anatomies and physiologies.
Jane Kilkenny, the vice president of magnetic resonance at Siemens Healthineers North America, said the MAGNETOM Viato.Mobile represents an opportunity to bring the capabilities of advanced imaging to patients who don’t have geographic proximity to facilities with these imaging systems.
“The MAGNETOM Viato.Mobile demonstrates our dedication to the mobile MR market by offering the latest and greatest technologies to patients who might lack convenient access to premium diagnostic MR scanners,” noted Kilkenny. “The introduction of the MAGNETOM Viato.Mobile is yet another example of our efforts to democratize high-end imaging technology to provide greater access to care.”
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.